Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder.
Chadwick
D
D
Hallett
M
M
Jenner
P
P
Marsden
C D
CD
D006916:5-Hydroxytryptophan / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D002998:Clonazepam / Q000627:therapeutic use; D005260:Female; D010134:Fenclonine / Q000627:therapeutic use; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D000860:Hypoxia / Q000150:complications*; D007520:Isocarboxazid / Q000627:therapeutic use; D008784:Methysergide / Q000627:therapeutic use; D009207:Myoclonus / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012701:Serotonin / Q000378:metabolism
D001569:Benzodiazepines; D012701:Serotonin; D007520:Isocarboxazid; D006897:Hydroxyindoleacetic Acid; D002998:Clonazepam; D006916:5-Hydroxytryptophan; D010134:Fenclonine; D008784:Methysergide